Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Neutrophil Integrins and Matrix Ligands and NET Release.

O'Brien XM, Reichner JS.

Front Immunol. 2016 Sep 19;7:363. Review.

2.

Beta-glucan contamination of pharmaceutical products: How much should we accept?

Barton C, Vigor K, Scott R, Jones P, Lentfer H, Bax HJ, Josephs DH, Karagiannis SN, Spicer JF.

Cancer Immunol Immunother. 2016 Nov;65(11):1289-1301. Review.

3.

Orally administered β-glucan attenuates the Th2 response in a model of airway hypersensitivity.

Burg AR, Quigley L, Jones AV, O'Connor GM, Boelte K, McVicar DW, Orr SJ.

Springerplus. 2016 Jun 21;5(1):815. doi: 10.1186/s40064-016-2501-1.

4.

Vaccine adjuvants as potential cancer immunotherapeutics.

Temizoz B, Kuroda E, Ishii KJ.

Int Immunol. 2016 Jul;28(7):329-38. doi: 10.1093/intimm/dxw015. Review.

5.

Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates.

Zent CS, Call TG, Bowen DA, Conte MJ, LaPlant BR, Witzig TE, Ansell SM, Weiner GJ.

Leuk Lymphoma. 2015;56(8):2373-8. doi: 10.3109/10428194.2015.1016932.

6.

Human polymorphonuclear neutrophils specifically recognize and kill cancerous cells.

Yan J, Kloecker G, Fleming C, Bousamra M 2nd, Hansen R, Hu X, Ding C, Cai Y, Xiang D, Donninger H, Eaton JW, Clark GJ.

Oncoimmunology. 2014 Jul 3;3(7):e950163.

7.

β-(1→3)-Glucan-mannitol conjugates: scope and amazing results.

Descroix K, Jamois F, Yvin JC, Vetvicka V, Ferrières V.

Ann Transl Med. 2014 Feb;2(2):12. doi: 10.3978/j.issn.2305-5839.2014.01.01.

8.

Recent advances in oral vaccine development: yeast-derived β-glucan particles.

De Smet R, Allais L, Cuvelier CA.

Hum Vaccin Immunother. 2014;10(5):1309-18. doi: 10.4161/hv.28166. Review.

9.

Binding of Soluble Yeast β-Glucan to Human Neutrophils and Monocytes is Complement-Dependent.

Bose N, Chan AS, Guerrero F, Maristany CM, Qiu X, Walsh RM, Ertelt KE, Jonas AB, Gorden KB, Dudney CM, Wurst LR, Danielson ME, Elmasry N, Magee AS, Patchen ML, Vasilakos JP.

Front Immunol. 2013 Aug 12;4:230. doi: 10.3389/fimmu.2013.00230.

10.

Immunostimulatory properties and antitumor activities of glucans (Review).

Vannucci L, Krizan J, Sima P, Stakheev D, Caja F, Rajsiglova L, Horak V, Saieh M.

Int J Oncol. 2013 Aug;43(2):357-64. doi: 10.3892/ijo.2013.1974. Review.

11.

Brucella β 1,2 cyclic glucan is an activator of human and mouse dendritic cells.

Martirosyan A, Pérez-Gutierrez C, Banchereau R, Dutartre H, Lecine P, Dullaers M, Mello M, Salcedo SP, Muller A, Leserman L, Levy Y, Zurawski G, Zurawski S, Moreno E, Moriyón I, Klechevsky E, Banchereau J, Oh S, Gorvel JP.

PLoS Pathog. 2012;8(11):e1002983. doi: 10.1371/journal.ppat.1002983.

12.

Up-regulation of GITRL on dendritic cells by WGP improves anti-tumor immunity in murine Lewis lung carcinoma.

Tian J, Ma J, Ma K, Ma B, Tang X, Baidoo SE, Tong J, Yan J, Lu L, Xu H, Wang S.

PLoS One. 2012;7(10):e46936. doi: 10.1371/journal.pone.0046936.

13.
14.

Relative contributions of dectin-1 and complement to immune responses to particulate β-glucans.

Huang H, Ostroff GR, Lee CK, Agarwal S, Ram S, Rice PA, Specht CA, Levitz SM.

J Immunol. 2012 Jul 1;189(1):312-7. doi: 10.4049/jimmunol.1200603.

15.

Preparation, characterization, and biological properties of β-glucans.

Rahar S, Swami G, Nagpal N, Nagpal MA, Singh GS.

J Adv Pharm Technol Res. 2011 Apr;2(2):94-103. doi: 10.4103/2231-4040.82953.

16.

Glucan-immunostimulant, adjuvant, potential drug.

Vetvicka V.

World J Clin Oncol. 2011 Feb 10;2(2):115-9. doi: 10.5306/wjco.v2.i2.115.

17.

Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived β-glucans.

Qi C, Cai Y, Gunn L, Ding C, Li B, Kloecker G, Qian K, Vasilakos J, Saijo S, Iwakura Y, Yannelli JR, Yan J.

Blood. 2011 Jun 23;117(25):6825-36. doi: 10.1182/blood-2011-02-339812.

18.

Orally administered particulate beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer.

Li B, Cai Y, Qi C, Hansen R, Ding C, Mitchell TC, Yan J.

Clin Cancer Res. 2010 Nov 1;16(21):5153-64. doi: 10.1158/1078-0432.CCR-10-0820.

19.

Commandeering a biological pathway using aptamer-derived molecular adaptors.

Mallik PK, Nishikawa K, Millis AJ, Shi H.

Nucleic Acids Res. 2010 Apr;38(7):e93. doi: 10.1093/nar/gkp1207.

20.

Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy.

Liu J, Gunn L, Hansen R, Yan J.

Exp Mol Pathol. 2009 Jun;86(3):208-14. doi: 10.1016/j.yexmp.2009.01.006. Review.

Supplemental Content

Support Center